AstraZeneca Partners with Saama to Integrate AI Platform for Accelerated Clinical Development

On October 17, Saama announced that it had signed a multi-year agreement with AstraZeneca.

This agreement aims to leverage Saama's artificial intelligence technology platform toSimplify and enhance AstraZeneca's clinical data management and medical review processes to accelerate clinical development and establish new standards.

Saama is an AI-based solutions provider aimed at accelerating clinical development and commercialization. It was founded by Suresh Katta in 1997 and is headquartered inCalifornia, USA。

As of now, Saama has completedTwo Rounds of Financing, totaling $75 million.

Under its umbrellaLife Science Analytics Cloud (LSAC) PlatformDeep learning technology can be used to collect, transform, analyze, model, and predict clinical data.

Currently, the LSAC platform has beenMore than 50Biotechnology company, inIn more than 1,500 studiesUse.

Previously, Pfizer and Merck collaborated with Saama to leverage LSAC platform technology for better extraction of clinical trial data, enhancing clinical research and development capabilities.

According to relevant information, the LSAC platform canData discovery time reduced by 35%，Save over 20,000+ hours of manual work time and nearly 50% of SDTM conversion time。

Lisa Moneymaker, Chief Technology Officer and Chief Product Officer of Saama, said: "The pharmaceutical industry is increasingly recognizing the need to fundamentally transform the way drugs are developed by adopting cutting-edge technologies."

She emphasized Saama's vision of accelerating drug development by utilizing its artificial intelligence technology platform, thereby providing essential treatments to patients more quickly. The collaboration with AstraZeneca demonstrates their joint commitment to redefining drug development practices for the benefit of patients worldwide.

According to the agreement, AstraZeneca will integrate Saama's platform into its data management and review systems.Combining Saama's Smart Data Quality (SDQ), Data Center, and Patient Insights Solutions, to achieve faster clinical database lock, more efficient data review and smarter medical review process.

Given AstraZeneca's extensive clinical product portfolio, AstraZeneca emphasized the importance of adopting cutting-edge technology to modernize data and medical review processes.

Natalie Fishburn, Vice President of AstraZeneca and Head of Clinical Operations in Biopharmaceutical R&D, believes that Saama's platform will serve as an internal driving force to automate tasks, streamline data flow, and leverage artificial intelligence for new solutions, ultimately advancing medical breakthroughs for patients.

Saama’s SDQ, data center, and patient insights solutions work together by leveraging advanced technology and artificial intelligence capabilities, enabling research teams to manage the extensive and diverse clinical trial data of today.

These solutions aggregate and standardize data from multiple sources, streamline medical review processes, enhance patient safety monitoring, predict participant behavior, and accelerate the discovery of clinical signals.

Reference link:

https://www.pharmafocusamerica.com/news/saama-enters-a-new-agreement-facilitating-ai-driven-drug-development